Roche's $4.3 billion Spark bid delayed again amid U.S., UK scrutiny
Swiss drugmaker Roche's $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again, possibly beyond the first half, as regulators continue...